Pfizer will retool its obesity drug efforts, but the delay is a blow to the group's ambitions to challenge Novo Nordisk and Lilly in the fast-developing space. Pfizer (NYSE: PFE) - shares slumped Friday after the drugmaker said it would not advance a study of its two-dose obesity treatment, following a high level of side effects in patients involved in the Phase...
Analyzing the options chain and the chart patterns of PFE Pfizer prior to the earnings report this week, I would consider purchasing the 30usd strike price at the money Calls with an expiration date of 2023-11-10, for a premium of approximately $0.91. If these options prove to be profitable prior to the earnings release, I would sell at least half of...
Pfizer's Stock: Is it Worth the Investment Amidst Challenges and Opportunities? Pfizer, a pharmaceutical powerhouse, has made headlines in recent years, primarily for its groundbreaking coronavirus vaccine. Despite achieving over $100 billion in annual revenue last year, the company's stock has witnessed a significant decline of approximately 35% in the current...
Its right at the support line and could rally towards 160. It must stay above 95, otherwise its going further down. Its tech analysis and not any advice to buy/sell.
Pfizer (PFE) has been trading within a Channel Down pattern since the start of the year and on Friday it registered the strongest green 1D candle since the recent Lower Low leg started in August. This is technically the start of the new rebound leg towards a new Lower High. Those have been priced within the 1D MA50 (blue trend-line) and 1D MA100 (green...
My name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️ I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise. This is how you build real long term...
Hello Traders Investors And Community, welcome to this analysis where we are looking at the 4-hour timeframe perspective of stock value PFIZER, the recent events, the current formation structure, what needs to be fulfilled that the stock confirms properly and what are possible trading opportunities when the stock has confirmed. As the main stock-market has...
Here's not much on the chart. But what you see is evident. The pitchforks median line is respected by price many times. And this time it's the same. But there's a reason why this time price could flush down to the L-MLH. Indexes are weaker and weaker. The first profit target for me is either the L-MLH, or the A/R (yellow) line. The Action/Reaction line is...
PFE weekly data is conveying significant accumulation at the current price range. Net positive volume has been increasing on a daily basis for the past few days -- in anticipation of the company's incoming price growth, long term. The stock is currently sitting at 78.6 FIB level -- a discounted level where buyers converge. Expect some significant bounce from...
My analysis is on the 2H. I am uniquely qualified in my fundamental analysis. This is a one day until earnings. My thesis is the earnings will stimulate what will be a breakout from a flat bottom triangle. I will buy one share of stock. I will spend a similar amount on call options striking $460 expiring August 11th. I see LLY as surging while PFE is a bit...
MRNA is a medical technology company. It is in the vaccine sector and competes ( well) with NVAX and PFE among others. Earnings are upcoming on 8/3 in about a week. On the 30 minute chart it appears to be in a descending wedge pattern which is typically a bottoming with a breakout over and beyond the descending trendline. The relative trend indicator shows...
Are you searching for a lucrative investment opportunity that promises great returns in 2023? Look no further as we unveil the hidden potential of Pfizer Pharmaceutical stock. In this blog post, we will delve into the compelling reasons why investing in Pfizer is not only a smart move but also an incredibly exciting. From groundbreaking innovations to robust...
Discussing a potential capital rotation trade. We analyze Tesla, Amazon, Pfizer, Moderna, Hershey, and others to get a sense of what is going on.
NVAX has had significant down trending over a wide range of time. On the 4H chart it seems to be pivoting from a swing bottom 3-4 days ago. This is accompanied by a cross of the MACD lines under the histogram on that indicator and a flip of volatility on the relative volatility indicator. NVAX has been subject to significant short selling. Price is presently...
Pfizer - Medium Term - We look to Sell at 39.88 (stop at 41.08) Bespoke resistance is located at 40. 40.14 has been pivotal. 40.37 has been pivotal. Daily signals are bearish. We look for a temporary move higher. Our profit targets will be 37.08 and 36.58 Resistance: 37.05 / 38.30 / 39.00 Support: 36.03 / 35.50 / 35.00 Please be advised that the...
Over the past year, investors have been disappointed with Pfizer as the company's stock experienced a significant decline of 28.8%. This decline can be attributed, in part, to the anticipated drop in sales for Pfizer's COVID-19 vaccine, Comirnaty, and its antiviral treatment, Paxlovid. However, there is an overlooked aspect that investors have failed to recognize:...
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under...
This strategy dissects the dual nature of big pharmaceutical firms like Johnson & Johnson, Pfizer, Moderna, and Merck & Co viewed through base Fibonacci Extension Clustering. Despite big pharma's significant contributions to healthcare, these firms have benefited from questionable practices, including price manipulation and exploiting addictions . Price...